Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Aug 07, 2015 5:35pm
200 Views
Post# 23999356

RE:RE:RE:When will the bleeding stop?

RE:RE:RE:When will the bleeding stop?Hi Ron.

These share prices represent a huge buying opportunity. I'm long and accumulating as I have the resources. Ever since July of 2013 there has not been one step backwards. It has been nothing but continuous scientific progress.

Yes it is true that trial design has been a serious problem in the past such as underpowering the ASSURE trial and using PAV as an endpoint. In fact, had the study been properly powered the PAV target may have been met with time.

But that is hind sight. It is easy for any armchair QB to criticise it. But knowledge is progressive and we know that rvx-208 has not been abandoned.

From what I see the big money continues to flow in and there will be more partners. Also, the scientific momentum continues in terms of the number, experience and influence of very high profile doctors and scientists in DM,CVD, CKD.and other inflammatory diseases..all highly related diseases.

I'm not a trading expert and I yet I know there are many investors with varying objectives...and that is great. I sense that there are many investors just sitting on the sidelines who will watch the milestones through the trial and start investing when the shares hit $3.00 and then $5.00 and then $10.00 and on and on because at the right point even coming in at $10.00 they know the money to be made. Various traders will make big dollars along the way but the real money will be in the CVR deal - initial payout, milestone payouts, successful trial payout and then the ongoing royalties. That is my target.

So consider the declining share price as a big positive...we all know what is coming.

Cheers from
Toinv      :)
  • Alias - hoity toity, fraudster, liar, humper, dumper, pumper, lumper and whatever other nonsense he/she/it calls me.


Bullboard Posts